[HTML] nature.comFull View

[HTML][HTML] Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - Nature …, 2022 - nature.com
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …
被引用次数：40 相关文章

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

ACTIV-2/A5401 Study Team - Nature …, 2022 - lanlexperts.elsevierpure.com
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - Nature …, 2022 - osti.gov
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - Nature …, 2022 - cdr.lib.unc.edu
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

ACTIV-2/A5401 Study Team - Nature …, 2022 - ohiostate.elsevierpure.com
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

KW Chew, C Moser, ES Daar, DA Wohl… - Nature …, 2022 - escholarship.org
Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics. Safety,
antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized controlled …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl… - Nature …, 2022 - econpapers.repec.org
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

KW Chew, C Moser, ES Daar, DA Wohl… - Nature …, 2022 - ui.adsabs.harvard.edu
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - Nature …, 2022 - europepmc.org
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

KW Chew, C Moser, ES Daar, DA Wohl, JZ Li… - 2022 - cabidigitallibrary.org
Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …